The landscape of targeted immunotherapy is shifting rapidly, with the Interleukin Inhibitors Market standing at the forefront of this medical revolution. These specialized biologics, designed to interrupt specific inflammatory signaling pathways, have transitioned from niche treatments to primary therapeutic options for a wide array of autoimmune conditions. As clinical understanding of...